List of Tyvaso Dpi drug patents

Tyvaso Dpi is owned by United Therap.

Tyvaso Dpi contains Treprostinil.

Tyvaso Dpi has a total of 6 drug patents out of which 0 drug patents have expired.

Tyvaso Dpi was authorised for market use on 23 May, 2022.

Tyvaso Dpi is available in powder;inhalation dosage forms.

Tyvaso Dpi can be used as method of treating pulmonary hypertension by administering treprostinil or a salt thereof by inhalation using a device.

The generics of Tyvaso Dpi are possible to be released after 01 April, 2035.

TYVASO DPI Litigations
Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9593066 UNITED THERAP Process to prepare treprostinil, the active ingredient in remodulin®
Dec, 2028

(5 years from now)

US9604901 UNITED THERAP Process to prepare treprostinil, the active ingredient in Remodulin®
Dec, 2028

(5 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10130685 UNITED THERAP Diketopiperazine salts for drug delivery and related methods
Aug, 2025

(2 years from now)

US10716793 UNITED THERAP Treprostinil administration by inhalation
May, 2027

(3 years from now)

US10772883 UNITED THERAP Diketopiperazine microparticles with defined specific surface areas
Jun, 2030

(7 years from now)

US10421729 UNITED THERAP Microcrystalline diketopiperazine compositions and methods
Apr, 2035

(11 years from now)

Do you want to check out TYVASO DPI patents from before 2022?

Drugs and Companies using TREPROSTINIL ingredient

Market Authorisation Date: 23 May, 2022

Treatment: Method of treating pulmonary hypertension by administering treprostinil or a salt thereof by inhalation using a device

Dosage: POWDER;INHALATION

More Information on Dosage

TYVASO DPI family patents

50

United States

18

Korea, Republic of

13

Japan

9

China

9

European Union

7

Spain

7

Australia

5

Canada

4

Hong Kong

4

Brazil

4

Israel

4

Mexico

3

Denmark

3

Poland

3

Singapore

3

Hungary

2

Malaysia

1

Russia

1

Argentina

1

Taiwan

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in